GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tanvex BioPharma 6541.TW · TWD

Health Care · Taiwan Stock Exchange · 🇹🇼 Taiwan

Compare

29.10

+4.49%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 401.0m

FY2016FY2025

Net income

−TWD 1.50bn

FY2016FY2025

Free cash flow

−TWD 1.68bn

FY2016FY2025

Shareholders' equity

TWD 5.69bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueTWD 401.0mTWD 34.7mTWD 61.4mTWD 22.4mTWD 5.4mTWD 300,000————
Research and developmentTWD 187.6mTWD 1.06bnTWD 1.71bnTWD 1.35bnTWD 1.38bnTWD 1.86bnTWD 2.00bnTWD 1.65bnTWD 1.08bnTWD 1.11bn
Operating income−TWD 1.39bn−TWD 1.36bn−TWD 2.11bn−TWD 1.60bn−TWD 1.50bn−TWD 2.09bn−TWD 2.26bn−TWD 1.95bn−TWD 1.40bn−TWD 1.35bn
Net income−TWD 1.50bn−TWD 1.38bn−TWD 2.14bn−TWD 1.64bn−TWD 1.54bn−TWD 2.10bn−TWD 2.27bn−TWD 1.89bn−TWD 1.41bn−TWD 1.24bn
Diluted earnings per share-5.70-8.42-15.80-13.54-13.31-21.03-25.60-22.92-20.65-18.32

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsTWD 7.96bnTWD 2.74bnTWD 2.76bnTWD 3.42bnTWD 4.71bnTWD 4.37bnTWD 3.57bnTWD 4.48bnTWD 3.97bnTWD 3.87bn
Cash and short-term investmentsTWD 878.7mTWD 377.0mTWD 380.8mTWD 786.2mTWD 2.22bnTWD 2.07bnTWD 2.43bnTWD 1.63bnTWD 3.06bnTWD 2.92bn
Total liabilitiesTWD 2.27bnTWD 1.84bnTWD 1.94bnTWD 2.03bnTWD 1.92bnTWD 1.75bnTWD 542.1mTWD 263.9mTWD 223.8mTWD 299.2m
DebtTWD 211.6mTWD 1.65bnTWD 1.73bnTWD 1.84bnTWD 1.76bnTWD 1.52bnTWD 342.7mTWD 54.5mTWD 59.1mTWD 66.1m
Shareholders' equityTWD 5.69bnTWD 893.3mTWD 821.1mTWD 1.39bnTWD 2.79bnTWD 2.62bnTWD 3.03bnTWD 4.21bnTWD 3.75bnTWD 3.57bn
Shares outstanding263m164m135m121m116m100m89m83m68m68m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−TWD 1.01bn−TWD 1.15bn−TWD 1.43bn−TWD 1.33bn−TWD 1.39bn−TWD 1.79bn−TWD 1.90bn−TWD 1.61bn−TWD 1.21bn−TWD 833.4m
Capital spending−TWD 670.2m−TWD 110.8m−TWD 71.3m−TWD 96.1m−TWD 30.3m−TWD 67.5m−TWD 93.6m−TWD 108.8m−TWD 116.6m−TWD 248.6m
Free cash flow−TWD 1.68bn−TWD 1.26bn−TWD 1.51bn−TWD 1.43bn−TWD 1.42bn−TWD 1.86bn−TWD 1.99bn−TWD 1.71bn−TWD 1.33bn−TWD 1.08bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueTWD 220.4mTWD 132.8mTWD 179.0mTWD 125.3mTWD 46.8mTWD 49.9mTWD 2.8mTWD 11.5m
Operating income−TWD 367.1m−TWD 400.2m−TWD 373.6m−TWD 286.1m−TWD 338.0m−TWD 461.4m−TWD 273.1m−TWD 314.9m
Net income−TWD 382.5m−TWD 388.7m−TWD 420.5m−TWD 273.5m−TWD 340.4m−TWD 465.7m−TWD 278.2m−TWD 318.5m
Diluted earnings per share-1.44-1.47-1.60-1.04-1.29-1.77-1.70-1.94
Cash from operations—−TWD 309.0m−TWD 166.0m−TWD 221.0m−TWD 328.0m−TWD 288.0m−TWD 284.0m−TWD 232.0m
Capital spending—−TWD 175.0m−TWD 465.0m−TWD 125.0m−TWD 68.0m−TWD 8.0m−TWD 32.0m−TWD 11.0m
Free cash flow—−TWD 484.0m−TWD 631.0m−TWD 346.0m−TWD 396.0m−TWD 296.0m−TWD 316.0m−TWD 243.0m
Total assets—TWD 7.64bnTWD 7.96bnTWD 8.18bnTWD 6.89bnTWD 7.65bnTWD 2.74bnTWD 2.99bn
Cash and short-term investments—TWD 442.2mTWD 878.7mTWD 1.39bnTWD 571.0mTWD 1.08bnTWD 377.0mTWD 742.1m
Debt—TWD 325.1mTWD 211.6mTWD 173.1mTWD 165.8mTWD 184.4mTWD 160.0mTWD 338.6m
Shareholders' equity—TWD 5.36bnTWD 5.69bnTWD 6.00bnTWD 4.87bnTWD 5.55bnTWD 893.3mTWD 1.15bn

Financial ratios

Data as of 2 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-346.2%-3916.2%-3433.1%-7123.7%-27749.0%-695214.0%
Net margin-374.1%-3983.9%-3480.0%-7325.2%-28546.3%-701412.0%
Return on equity-26.3%-154.7%-260.3%-117.9%-55.2%-80.3%
Return on assets-18.8%-50.5%-77.3%-48.0%-32.7%-48.1%
Free cash flow yield-4.3%-21.4%-34.0%-34.5%-39.5%-58.1%
Revenue growth1056.3%-43.5%174.1%314.4%1702.0%—
Earnings growth8.6%-35.4%30.2%6.3%-26.7%-7.5%
Current ratio1.87x1.94x1.66x3.44x9.67x6.41x
Debt to equity0.04x0.18x0.20x0.09x0.03x0.06x
Equity ratio71.5%32.7%29.7%40.7%59.3%59.9%
Interest coverage-29.39x-25.46x-36.74x-29.17x-32.45x-112.31x
R&D as a share of sales46.8%3052.4%2779.2%6032.1%25592.3%620200.0%
Buybacks as a share of market value-60.5%-21.3%-11.6%-4.5%-15.8%-12.6%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue161.6%321.9%—
Operating income-4.5%-7.8%5.3%
Net income-2.9%-6.5%6.0%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-630.4%-1241.8%-1911.1%—
Net margin-661.5%-1282.1%-1962.7%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-9.7-7.7-4.1-7.6-12.8-5.2-5.0-7.7-10.3-23.7
Price to sales36.1308.5143.4———————

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 1000-to-333.577 reverse split · 13 Mar 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.